UBS Group Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price

Zoetis (NYSE:ZTS) had its price target dropped by equities research analysts at UBS Group from $85.00 to $80.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price target would indicate a potential upside of 10.30% from the company’s current price.

ZTS has been the subject of a number of other reports. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday. HSBC dropped their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Morgan Stanley set a $85.00 price target on Zoetis in a research note on Friday. Barclays lowered their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Finally, TD Cowen cut their target price on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus price target of $115.50.

Zoetis Stock Down 6.1%

Shares of ZTS traded down $4.74 during trading hours on Friday, reaching $72.53. The stock had a trading volume of 12,770,194 shares, compared to its average volume of 5,795,663. Zoetis has a 12 month low of $71.47 and a 12 month high of $160.48. The firm has a 50-day simple moving average of $76.66 and a 200 day simple moving average of $100.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The company has a market capitalization of $30.41 billion, a price-to-earnings ratio of 12.03, a P/E/G ratio of 1.16 and a beta of 0.74.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the previous year, the business posted $1.76 EPS. Zoetis’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts predict that Zoetis will post 6.87 earnings per share for the current fiscal year.

Insider Transactions at Zoetis

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 11,650 shares of company stock worth $886,384 in the last 90 days. Insiders own 0.22% of the company’s stock.

Institutional Investors Weigh In On Zoetis

Large investors have recently made changes to their positions in the business. J. Stern & Co. LLP raised its position in Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. Norges Bank purchased a new position in Zoetis in the fourth quarter valued at about $734,425,000. Vanguard Group Inc. grew its position in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares during the period. BlackRock Inc. grew its position in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. Finally, Ruane Cunniff & Goldfarb L.P. purchased a new stake in shares of Zoetis during the 1st quarter worth approximately $286,660,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.